The epigenetic immunomodulator, HBI8000, enhances the response and reverses resistance to checkpoint inhibitors

Treatment with immune checkpoint inhibitors (ICIs) targeting CTLA-4 and the PD-1/PD-L1 axis is effective against many cancer types. However, due in part to unresponsiveness or acquired resistance, not all patients experience a durable response to ICIs.